Myriad Genetics, a healthcare products manufacturer based in Salt Lake City, Utah, announced that Myriad RBM, a subsidiary, has entered a researchment collaboration with Sanofi and the Population Health Research Institute (PHRI). With this collaboration, the company will conduct protein biomarker research for ORIGIN, the Outcome Reduction with Initial Glargine Intervention study.
ORIGIN is the largest and longest ongoing clinical trial for early and pre-diabetes. According to a press release by the company, PHRI will analyze the relationship between protein biomarker results and their clinical outcomes.
According to the agreement, the Myriad Genetics subsidiary will analyze serum samples that were collected as part of the ORIGIN. The company’s DiscoveryMAP quantitative immunoassay panel will be used for the analysis of the serum samples. ORIGIN is a six-year cardiovascular outcomes clinical trial that evaluates Lantus (insulin glargine) against traditional care in 12,500 patients with pre-diabetes or early type two diabetes. The randomized clinical trial includes patients in 40 countries around the world.
Dr. Matt McQueen is the research laboratory director at PHRI. In prepared remarks, he said, “This biomarker project using DiscoveryMAP is a logical extension of the landmark ORIGIN study." He continued, "The measurement of hundreds of relevant proteins in metabolic, inflammatory and other important pathways has the potential to improve treatment protocols for diabetes."
The collaboration will lead to an estimated $10 million in service revenue for Myriad over the next 24 months.